These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

250 related items for PubMed ID: 31244934

  • 1. Highly sensitive quantification of Alzheimer's disease biomarkers by aptamer-assisted amplification.
    Chan HN, Xu D, Ho SL, He D, Wong MS, Li HW.
    Theranostics; 2019; 9(10):2939-2949. PubMed ID: 31244934
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Proteomic analysis of cerebrospinal fluid in Alzheimer's disease: wanted dead or alive.
    Oláh Z, Kálmán J, Tóth ME, Zvara Á, Sántha M, Ivitz E, Janka Z, Pákáski M.
    J Alzheimers Dis; 2015; 44(4):1303-12. PubMed ID: 25428253
    [Abstract] [Full Text] [Related]

  • 4. Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease.
    Kang JH, Vanderstichele H, Trojanowski JQ, Shaw LM.
    Methods; 2012 Apr; 56(4):484-93. PubMed ID: 22503777
    [Abstract] [Full Text] [Related]

  • 5. Robust and Universal SERS Sensing Platform for Multiplexed Detection of Alzheimer's Disease Core Biomarkers Using PAapt-AuNPs Conjugates.
    Zhang X, Liu S, Song X, Wang H, Wang J, Wang Y, Huang J, Yu J.
    ACS Sens; 2019 Aug 23; 4(8):2140-2149. PubMed ID: 31353891
    [Abstract] [Full Text] [Related]

  • 6. Cost-effectiveness of the use of biomarkers in cerebrospinal fluid for Alzheimer's disease.
    Valcárcel-Nazco C, Perestelo-Pérez L, Molinuevo JL, Mar J, Castilla I, Serrano-Aguilar P.
    J Alzheimers Dis; 2014 Aug 23; 42(3):777-88. PubMed ID: 24916543
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. A two-step immunoassay for the simultaneous assessment of Aβ38, Aβ40 and Aβ42 in human blood plasma supports the Aβ42/Aβ40 ratio as a promising biomarker candidate of Alzheimer's disease.
    Shahpasand-Kroner H, Klafki HW, Bauer C, Schuchhardt J, Hüttenrauch M, Stazi M, Bouter C, Wirths O, Vogelgsang J, Wiltfang J.
    Alzheimers Res Ther; 2018 Dec 08; 10(1):121. PubMed ID: 30526652
    [Abstract] [Full Text] [Related]

  • 9. Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.
    Thaweepoksomboon J, Senanarong V, Poungvarin N, Chakorn T, Siwasariyanon N, Washirutmangkur L, Udompunthuruk S.
    J Med Assoc Thai; 2011 Feb 08; 94 Suppl 1():S77-83. PubMed ID: 21721431
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Mass-Spectrometry-Based Method To Quantify in Parallel Tau and Amyloid β 1-42 in CSF for the Diagnosis of Alzheimer's Disease.
    Pottiez G, Yang L, Stewart T, Song N, Aro P, Galasko DR, Quinn JF, Peskind ER, Shi M, Zhang J.
    J Proteome Res; 2017 Mar 03; 16(3):1228-1238. PubMed ID: 28112948
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Biomarkers for Alzheimer's disease.
    Pauwels EK, Volterrani D, Mariani G.
    Drug News Perspect; 2009 Apr 03; 22(3):151-60. PubMed ID: 19440558
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Advances in the development of biomarkers for Alzheimer's disease: from CSF total tau and Abeta(1-42) proteins to phosphorylated tau protein.
    Hampel H, Goernitz A, Buerger K.
    Brain Res Bull; 2003 Aug 15; 61(3):243-53. PubMed ID: 12909294
    [Abstract] [Full Text] [Related]

  • 16. Improved Differential Diagnosis of Alzheimer's Disease by Integrating ELISA and Mass Spectrometry-Based Cerebrospinal Fluid Biomarkers.
    Khoonsari PE, Shevchenko G, Herman S, Remnestål J, Giedraitis V, Brundin R, Degerman Gunnarsson M, Kilander L, Zetterberg H, Nilsson P, Lannfelt L, Ingelsson M, Kultima K.
    J Alzheimers Dis; 2019 Aug 15; 67(2):639-651. PubMed ID: 30614806
    [Abstract] [Full Text] [Related]

  • 17. Advances in the detection of Alzheimer's disease-use of cerebrospinal fluid biomarkers.
    Sjögren M, Andreasen N, Blennow K.
    Clin Chim Acta; 2003 Jun 15; 332(1-2):1-10. PubMed ID: 12763273
    [Abstract] [Full Text] [Related]

  • 18. Biomarkers for Alzheimer's disease: current status and prospects for the future.
    Blennow K, Zetterberg H.
    J Intern Med; 2018 Dec 15; 284(6):643-663. PubMed ID: 30051512
    [Abstract] [Full Text] [Related]

  • 19. T1rho MRI and CSF biomarkers in diagnosis of Alzheimer's disease.
    Haris M, Yadav SK, Rizwan A, Singh A, Cai K, Kaura D, Wang E, Davatzikos C, Trojanowski JQ, Melhem ER, Marincola FM, Borthakur A.
    Neuroimage Clin; 2015 Dec 15; 7():598-604. PubMed ID: 25844314
    [Abstract] [Full Text] [Related]

  • 20. Critical Comparison of Different Biomarkers for Alzheimer's Disease in a Clinical Setting.
    Weise D, Tiepolt S, Awissus C, Hoffmann KT, Lobsien D, Kaiser T, Barthel H, Sabri O, Gertz HJ.
    J Alzheimers Dis; 2015 Dec 15; 48(2):425-32. PubMed ID: 26402006
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.